Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
NCT07481981 Treprostinil palmitil Familial Primary Pulmonary Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07481981 Treprostinil palmitil Familial Primary Pulmonary Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07481981 clinical trial report covering Treprostinil palmitil, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07483632 Fingolimod Hydrochloride Multiple sclerosis relapse Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07483632 Fingolimod Hydrochloride Multiple sclerosis relapse Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07483632 clinical trial report covering Fingolimod Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07482787 Allantoin Epidermolysis Bullosa Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07482787 Allantoin Epidermolysis Bullosa Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07482787 clinical trial report covering Allantoin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07482813 Allantoin Epidermolysis Bullosa Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07482813 Allantoin Epidermolysis Bullosa Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07482813 clinical trial report covering Allantoin, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07485855 Influenza Vaccine, Adjuvanted(Seqirus GmbH) Chronic leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07485855 Influenza Vaccine, Adjuvanted(Seqirus GmbH) Chronic leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07485855 clinical trial report covering Influenza Vaccine, Adjuvanted(Seqirus GmbH), Phase 3, endpoints, sponsor, geography, readout timing and developm
Read →
NCT07484217 Solriamfetol Hydrochloride Excessive Daytime Sleepiness Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07484217 Solriamfetol Hydrochloride Excessive Daytime Sleepiness Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07484217 clinical trial report covering Solriamfetol Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
CTR20261066 Artificial Bear Bile Powder Acute pharyngitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
CTR20261066 Artificial Bear Bile Powder Acute pharyngitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
CTR20261066 clinical trial report covering Artificial Bear Bile Powder, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07486687 Pembrolizumab Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07486687 Pembrolizumab Triple Negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07486687 clinical trial report covering Pembrolizumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07486544 Dexamethasone Pharyngitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07486544 Dexamethasone Pharyngitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07486544 clinical trial report covering Dexamethasone, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07486479 Venetoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07486479 Venetoclax Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07486479 clinical trial report covering Venetoclax, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07486583 Desloratadine Chronic Urticaria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07486583 Desloratadine Chronic Urticaria Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07486583 clinical trial report covering Desloratadine, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →
NCT07484230 Itepekimab Nasal Polyps Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
Latest Hotspot
8 min read
NCT07484230 Itepekimab Nasal Polyps Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
17 August 2026
NCT07484230 clinical trial report covering Itepekimab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Read →